— New Data Show Patients Spend Significantly Less Time in Hospital(1)
— Survival Benefit Widens in Second Year
SAN FRANCISCO, CA–(Marketwire – Nov 10, 2011) – Edwards Lifesciences Corporation (NYSE: EW), the global leader in the science of heart valves and hemodynamic monitoring, today announced two-year results of a pivotal clinical study of inoperable patients with severe aortic stenosis treated with the Edwards SAPIEN transcatheter heart valve, which was approved last week by the United States Food and Drug Administration (FDA). These data from The PARTNER Trial (Cohort B) demonstrated a widening survival benefit for SAPIEN valve patients at two years, including significantly less time spent in the hospital. The new results were presented today at the 23rd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation….
http://www.marketwire.com/press-release/edwards-sapien-valves-patient-benefits-increase-at-two-years-nyse-ew-1585491.htm
